 Eli Lilly  Co said the US Food and Drug Administration wont approve its new drug application for a type diabetes treatment until issues at the product manufacturing facility are resolved Lilly said Wednesday that it received a complete response letter from the FDA that referenced deficiencies at the Boehringer Ingelheim Pharmaceutical Inc facility where its diabetes treatment empagliflozin will be manufactured A
  